RGEN
NASDAQ · Life Sciences Tools & Services
Repligen Corp
$173.49
+5.01 (+2.97%)
Financial Highlights (FY 2026)
Revenue
827.34M
Net Income
54.79M
Gross Margin
52.6%
Profit Margin
6.6%
Rev Growth
-2.7%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 52.6% | 52.6% | 33.3% | 33.3% |
| Operating Margin | 7.5% | 6.7% | 6.8% | 6.5% |
| Profit Margin | 6.6% | 6.3% | 7.1% | 6.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 827.34M | 850.29M | 4.59B | 4.00B |
| Gross Profit | 435.59M | 447.68M | 1.53B | 1.33B |
| Operating Income | 61.80M | 57.17M | 311.12M | 261.18M |
| Net Income | 54.79M | 50.68M | 325.04M | 256.90M |
| Gross Margin | 52.6% | 52.6% | 33.3% | 33.3% |
| Operating Margin | 7.5% | 6.7% | 6.8% | 6.5% |
| Profit Margin | 6.6% | 6.3% | 7.1% | 6.4% |
| Rev Growth | -2.7% | -2.7% | +1.3% | +8.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.13B | 1.13B | 1.77B | 1.35B |
| Total Equity | 4.37B | 4.37B | 3.56B | 3.35B |
| D/E Ratio | 0.26 | 0.26 | 0.50 | 0.40 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 150.07M | 146.52M | 499.02M | 399.89M |
| Free Cash Flow | — | — | 285.62M | 226.18M |